Paulus Kirchhof: Anticoagulation in Patients with a Single CHADS-VA Risk Factor
Paulus Kirchhof, Professor of Cardiovascular Medicine at the University of Birmingham, Professor of Medicine (Cardiology) and Director of the Department of Cardiology at the University Medical Center Hamburg-Eppendorf, shared a post on LinkedIn about his recent article, published in NEJM, adding:
“Anticoagulation in patients with a single CHADS-VA risk factor.
SINGLE-AF is an important trial that will inform clinical decisions.
The full paper is now available at the NEJM.
Many congratulations to all who realised SINGLE AF!
You can read my thoughts on SINGLE AF and on the use of anticoagulants in patients with atrial fibrillation and a single CHADS-VA risk factor here.
What is your take on anticoagulation in patients with atrial fibrillation and a single CHADS-VA risk factor?”
Title: Anticoagulation for Atrial Fibrillation with a Single Risk Factor for Stroke
Author: Paulus Kirchhof
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 20, 2026, 06:45Grant Garcia: Why Does a Blood Clot Diagnosis Immediately End an Athlete’s Season?
-
Oct 20, 2026, 06:35Parag Tamhankar: Landmark Study Reveals Genetic Spectrum and Targeted Therapies for ALPS in the Indian Population
-
Oct 20, 2026, 06:26Nina Houben: Neonatal Blood Transfusion Symposium and PhD Defense
-
Oct 20, 2026, 05:46Jan T. Kielstein: DNP Poisoning and Hemoadsorption The Limits of Rescue Therapy
-
Oct 20, 2026, 05:33Giulia Di Paolo: Connecting Plasma Donation to the Patients Who Depend on It
-
Oct 20, 2026, 05:20James Knowles: Exploring Plasma Manufacturing and Strengthening Industry Collaboration
-
Oct 20, 2026, 05:11Giuseppe Lippi։ Understanding Liver Test Abnormalities After AAV Gene Therapy
-
Oct 20, 2026, 05:02Sanam Loghavi: Test Your Hematology Knowledge at ASH 2026!
-
Oct 20, 2026, 04:13Ifeanyichukwu Ifechidere: DOACs Are Not the Answer to Every Anticoagulation Question